Generic Suboxone Availability

Last updated on Jun 11, 2025.

Suboxone is a brand name of buprenorphine/naloxone, approved by the FDA in the following formulation(s):

SUBOXONE (buprenorphine hydrochloride; naloxone hydrochloride - film;buccal, sublingual)

• Manufacturer: INDIVIOR
  Approval date: August 30, 2010
  Strength(s): EQ 2MG BASE;EQ 0.5MG BASE ^{[RLD] [AB]}, EQ 8MG BASE;EQ 2MG BASE ^{[RLD] [AB]}
• Manufacturer: INDIVIOR
  Approval date: August 10, 2012
  Strength(s): EQ 4MG BASE;EQ 1MG BASE ^{[RLD] [AB]}, EQ 12MG BASE;EQ 3MG BASE ^{[RLD] [AB]}

SUBOXONE (buprenorphine hydrochloride; naloxone hydrochloride - tablet;sublingual)

• Manufacturer: INDIVIOR
  Approval date: October 8, 2002
  Strength(s): EQ 2MG BASE;EQ 0.5MG BASE (discontinued) ^[RLD], EQ 8MG BASE;EQ 2MG BASE (discontinued) ^[RLD]

Is there a generic version of Suboxone available?

A generic version of Suboxone has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Suboxone and have been approved by the FDA:

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE (buprenorphine hydrochloride; naloxone hydrochloride film;buccal, sublingual)

• Manufacturer: ALVOGEN
  Approval date: January 24, 2019
  Strength(s): EQ 2MG BASE;EQ 0.5MG BASE ^[AB], EQ 4MG BASE;EQ 1MG BASE ^[AB], EQ 8MG BASE;EQ 2MG BASE ^[AB], EQ 12MG BASE;EQ 3MG BASE ^[AB]
• Manufacturer: DIFGEN PHARMS
  Approval date: June 2, 2022
  Strength(s): EQ 8MG BASE;EQ 2MG BASE ^[AB], EQ 12MG BASE;EQ 3MG BASE ^[AB]
• Manufacturer: DIFGEN PHARMS
  Approval date: February 13, 2025
  Strength(s): EQ 2MG BASE;EQ 0.5MG BASE ^[AB], EQ 4MG BASE;EQ 1MG BASE ^[AB]
• Manufacturer: DR REDDYS LABS SA
  Approval date: June 14, 2018
  Strength(s): EQ 2MG BASE;EQ 0.5MG BASE ^[AB], EQ 4MG BASE;EQ 1MG BASE ^[AB], EQ 8MG BASE;EQ 2MG BASE ^[AB], EQ 12MG BASE;EQ 3MG BASE ^[AB]
• Manufacturer: MYLAN TECHNOLOGIES
  Approval date: June 14, 2018
  Strength(s): EQ 8MG BASE;EQ 2MG BASE ^[AB], EQ 12MG BASE;EQ 3MG BASE ^[AB]
• Manufacturer: MYLAN TECHNOLOGIES
  Approval date: April 17, 2020
  Strength(s): EQ 2MG BASE;EQ 0.5MG BASE ^[AB], EQ 4MG BASE;EQ 1MG BASE ^[AB]

Note: No generic formulation of the following product is available.

• buprenorphine hydrochloride; naloxone hydrochloride - tablet;sublingual

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Suboxone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Sublingual and buccal film compositions
  Patent 11,135,216
  Issued: October 5, 2021
  Inventor(s): Myers Garry L. & Hilbert Samuel D. & Boone Bill J. & Bogue Beuford Arlie & Sanghvi Pradeep & Hariharan Madhusudan
  Assignee(s): Indivior UK Limited
  

  The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

  Patent expiration dates:

  • August 7, 2029
    
    ✓ 
    Patent use: TREATING OPIOID USE DISORDER
    ✓ 
    Drug product
• Sublingual and buccal film compositions
  Patent 8,475,832
  Issued: July 2, 2013
  Inventor(s): Myers Garry L. & Hilbert Samuel D. & Boone Bill J. & Bogue B. Arlie & Sanghvi Pradeep & Hariharan Madhusudan
  Assignee(s): RB Pharmaceuticals Limited
  

  The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

  Patent expiration dates:

  • March 26, 2030
    
    ✓ 
    Patent use: THIS DRUG IS ADMINISTERED BY SUBLINGUAL ROUTE TO HUMANS FOR MAINTENANCE TREATMENT OF OPIOID DEPENDENCE
    ✓ 
    Drug product
• Sublingual and buccal film compositions
  Patent 9,687,454
  Issued: June 27, 2017
  Inventor(s): Myers Garry L. & Hilbert Samuel D. & Boone Bill J. & Bogue Beuford Arlie & Sanghvi Pradeep & Hariharan Madhusudan
  Assignee(s): Indivior UK Limited
  

  The present invention relates to products and methods for treatment of narcotic dependence in a user. The invention more particularly relates to self-supporting dosage forms which provide an active agent for treating narcotic dependence while providing sufficient buccal adhesion of the dosage form.

  Patent expiration dates:

  • August 7, 2029
    
    ✓ 
    Patent use: TREATMENT OF OPIOID DEPENDENCE/SUBLINGUAL OR BUCCAL APPLICATION
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer